Dimensional Fund Advisors LP Sells 7,853 Shares of CareDx, Inc (NASDAQ:CDNA)

Dimensional Fund Advisors LP lessened its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 743,004 shares of the company’s stock after selling 7,853 shares during the period. Dimensional Fund Advisors LP owned approximately 1.39% of CareDx worth $15,907,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Thompson Davis & CO. Inc. boosted its stake in shares of CareDx by 6.3% during the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock worth $344,000 after buying an additional 950 shares during the last quarter. Legal & General Group Plc boosted its position in CareDx by 1.3% during the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company’s stock valued at $1,922,000 after purchasing an additional 1,118 shares during the last quarter. Sterling Capital Management LLC boosted its position in CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after purchasing an additional 1,126 shares during the last quarter. Principal Financial Group Inc. grew its stake in CareDx by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company’s stock valued at $406,000 after purchasing an additional 1,151 shares in the last quarter. Finally, Plato Investment Management Ltd raised its stake in shares of CareDx by 34.1% during the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock worth $116,000 after purchasing an additional 1,370 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CDNA shares. Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and lowered their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Stephens reaffirmed an “overweight” rating and issued a $40.00 target price on shares of CareDx in a report on Monday. HC Wainwright reiterated a “neutral” rating and set a $25.00 price target on shares of CareDx in a report on Monday. StockNews.com lowered CareDx from a “buy” rating to a “hold” rating in a research note on Monday. Finally, The Goldman Sachs Group reduced their target price on CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CareDx currently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

Insider Activity

In other CareDx news, Director Peter Maag sold 13,281 shares of CareDx stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total value of $228,831.63. Following the transaction, the director now owns 316,743 shares in the company, valued at $5,457,481.89. The trade was a 4.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christine Cournoyer sold 16,700 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the transaction, the director now directly owns 37,045 shares of the company’s stock, valued at approximately $523,445.85. The trade was a 31.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,246 shares of company stock worth $469,498. 4.90% of the stock is currently owned by company insiders.

CareDx Trading Up 4.4 %

NASDAQ:CDNA opened at $15.42 on Friday. The stock has a 50 day simple moving average of $17.97 and a 200 day simple moving average of $21.21. CareDx, Inc has a 1-year low of $9.99 and a 1-year high of $34.84. The stock has a market cap of $858.49 million, a P/E ratio of -5.71 and a beta of 2.27.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. During the same period last year, the firm earned ($0.03) earnings per share. CareDx’s revenue for the quarter was up 17.6% compared to the same quarter last year. As a group, sell-side analysts forecast that CareDx, Inc will post -0.9 EPS for the current year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.